Cargando…
A Longitudinal Observational Study of Medical Cannabis Use and Polypharmacy among Patients Presenting to Dispensaries in Pennsylvania
Background: Cannabis use is increasing among adults to treat a variety of health conditions. Given the potential for interactions and adverse events, it is important to assess the use of medical cannabis along with other concomitant medications when assessing for polypharmacy. Methods: The objective...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855524/ https://www.ncbi.nlm.nih.gov/pubmed/36672666 http://dx.doi.org/10.3390/biomedicines11010158 |
_version_ | 1784873400654626816 |
---|---|
author | Hajjar, Emily R. Herens, Allison Kelly, Erin L. Madden, Kayla Lungen, Jessica M. Worster, Brooke K. |
author_facet | Hajjar, Emily R. Herens, Allison Kelly, Erin L. Madden, Kayla Lungen, Jessica M. Worster, Brooke K. |
author_sort | Hajjar, Emily R. |
collection | PubMed |
description | Background: Cannabis use is increasing among adults to treat a variety of health conditions. Given the potential for interactions and adverse events, it is important to assess the use of medical cannabis along with other concomitant medications when assessing for polypharmacy. Methods: The objective of this observational, longitudinal study was to examine medical cannabis (MC) use along with concomitant medications over 12 months in patients with serious medical conditions enrolled in the Pennsylvania (PA) Department of Health’s (DOH) Medical Marijuana Program and to collect and catalog which forms of MC patients are taking along with their concomitant medications. Results: There were 213 participants who completed the baseline surveys in full, and 201, 187, and 175 who completed the 1, 6, and 12-month follow-up surveys. The mean age of the participants was 41.3 years, and 54.5% were female. The mean number of MC products taken at baseline was 3.41 and 3.47 at the 12-month survey. Participants took an average of 3.76 (SD 3.15) medications at baseline and 3.65 (SD 3.4) at 12 months. Most commonly used concomitant medications at baseline included vitamins (42.3%), antidepressants (29.1%), analgesics (22.1%), herbal products (19.7%), and anxiolytics (17.8%). Conclusion: Participants used multiple medical cannabis products to treat a number of medication conditions in conjunction with multiple medications. |
format | Online Article Text |
id | pubmed-9855524 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98555242023-01-21 A Longitudinal Observational Study of Medical Cannabis Use and Polypharmacy among Patients Presenting to Dispensaries in Pennsylvania Hajjar, Emily R. Herens, Allison Kelly, Erin L. Madden, Kayla Lungen, Jessica M. Worster, Brooke K. Biomedicines Article Background: Cannabis use is increasing among adults to treat a variety of health conditions. Given the potential for interactions and adverse events, it is important to assess the use of medical cannabis along with other concomitant medications when assessing for polypharmacy. Methods: The objective of this observational, longitudinal study was to examine medical cannabis (MC) use along with concomitant medications over 12 months in patients with serious medical conditions enrolled in the Pennsylvania (PA) Department of Health’s (DOH) Medical Marijuana Program and to collect and catalog which forms of MC patients are taking along with their concomitant medications. Results: There were 213 participants who completed the baseline surveys in full, and 201, 187, and 175 who completed the 1, 6, and 12-month follow-up surveys. The mean age of the participants was 41.3 years, and 54.5% were female. The mean number of MC products taken at baseline was 3.41 and 3.47 at the 12-month survey. Participants took an average of 3.76 (SD 3.15) medications at baseline and 3.65 (SD 3.4) at 12 months. Most commonly used concomitant medications at baseline included vitamins (42.3%), antidepressants (29.1%), analgesics (22.1%), herbal products (19.7%), and anxiolytics (17.8%). Conclusion: Participants used multiple medical cannabis products to treat a number of medication conditions in conjunction with multiple medications. MDPI 2023-01-08 /pmc/articles/PMC9855524/ /pubmed/36672666 http://dx.doi.org/10.3390/biomedicines11010158 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hajjar, Emily R. Herens, Allison Kelly, Erin L. Madden, Kayla Lungen, Jessica M. Worster, Brooke K. A Longitudinal Observational Study of Medical Cannabis Use and Polypharmacy among Patients Presenting to Dispensaries in Pennsylvania |
title | A Longitudinal Observational Study of Medical Cannabis Use and Polypharmacy among Patients Presenting to Dispensaries in Pennsylvania |
title_full | A Longitudinal Observational Study of Medical Cannabis Use and Polypharmacy among Patients Presenting to Dispensaries in Pennsylvania |
title_fullStr | A Longitudinal Observational Study of Medical Cannabis Use and Polypharmacy among Patients Presenting to Dispensaries in Pennsylvania |
title_full_unstemmed | A Longitudinal Observational Study of Medical Cannabis Use and Polypharmacy among Patients Presenting to Dispensaries in Pennsylvania |
title_short | A Longitudinal Observational Study of Medical Cannabis Use and Polypharmacy among Patients Presenting to Dispensaries in Pennsylvania |
title_sort | longitudinal observational study of medical cannabis use and polypharmacy among patients presenting to dispensaries in pennsylvania |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9855524/ https://www.ncbi.nlm.nih.gov/pubmed/36672666 http://dx.doi.org/10.3390/biomedicines11010158 |
work_keys_str_mv | AT hajjaremilyr alongitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania AT herensallison alongitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania AT kellyerinl alongitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania AT maddenkayla alongitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania AT lungenjessicam alongitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania AT worsterbrookek alongitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania AT hajjaremilyr longitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania AT herensallison longitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania AT kellyerinl longitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania AT maddenkayla longitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania AT lungenjessicam longitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania AT worsterbrookek longitudinalobservationalstudyofmedicalcannabisuseandpolypharmacyamongpatientspresentingtodispensariesinpennsylvania |